CG
DYN icon

Cutler Group’s Dyne Therapeutics DYN Stock Holding History

Cutler Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$8K Buy
+300
New +$6.79K ﹤0.01% 1368

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cutler Group's DYN Position: Q1 2024 in Review

Cutler Group opened a new position in Dyne Therapeutics (DYN) in Q1 2024: 300 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #1368 among its holdings.

169 funds tracked by Wall St. Rank hold DYN as of Q1 2024.

  • Cutler Group held 300 shares of Dyne Therapeutics worth $8K as of Q1 2024.
  • Dyne Therapeutics was a new Cutler Group position in Q1 2024.
  • Dyne Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1368 holding.
  • 169 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.